MetaCap

ANI Pharmaceuticals (ANIP) vs Korsana Biosciences (KRSA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Korsana Biosciences (KRSA) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 262.5% versus a loss of 14.0%. Over five years, ANIP leads with a +68.1% price change compared with -89.0% for KRSA. Korsana Biosciences is the larger company by market cap ($1.71 billion vs $1.56 billion), about 1.1 times the size, while ANI Pharmaceuticals is growing revenue faster (+43.8% vs +3.7%).

ANI Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.9% versus -170.1%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIP-14.01%KRSA+262.55%
+349%+152%-45%
Nov 21, 20251 yearNov 20, 2026
ANIP+57.44%KRSA-88.44%
+136%+13%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIP versus KRSA key metrics
MetricANIPKRSA
Share price$68.55$37.56
Market cap$1.56B$1.71B
1-day change-0.84%+5.95%
YTD return-13.16%+322.50%
1-year return-14.01%+262.55%
5-year return+68.14%-89.05%
P/E ratio (TTM)13.90—
Forward P/E6.72—
EPS (TTM)$4.93$-16.14
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$883.37M$2.07M
Revenue growth (YoY)+43.78%+3.70%
Net income (latest FY)$78.34M$-3.53M
Gross margin61.36%—
Operating margin12.58%-239.78%
Net margin8.87%-170.11%
52-week high$87.76$59.36
52-week low$67.14$7.19
Distance from 52-week high-21.89%-36.73%
Analyst consensusbuystrong_buy
Avg. price target upside+50.81%+17.15%
Average volume420.66K119.71K
Shares outstanding22.72M45.54M
Employees97019
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • KRSA has outperformed ANIP by 276.6 percentage points over the past year.
  • ANI Pharmaceuticals is more profitable, keeping 8.9 cents of every revenue dollar as net income versus -170.1 cents for Korsana Biosciences.
  • ANI Pharmaceuticals grew revenue faster in its latest fiscal year (+43.78% vs +3.70%).

About ANI Pharmaceuticals

ANIP stock →

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees

About Korsana Biosciences

KRSA stock →

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 19 employees

ANIP vs KRSA FAQ

Which is bigger, ANI Pharmaceuticals or Korsana Biosciences?

Korsana Biosciences (KRSA) is larger, with a market capitalization of $1.71B compared with $1.56B for ANI Pharmaceuticals (ANIP).

Which stock has performed better over the past year, ANIP or KRSA?

KRSA returned +262.55% over the past 12 months, compared with -14.01% for ANIP (price return, excluding dividends). Past performance does not predict future results.

Are ANI Pharmaceuticals and Korsana Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons